InVivoMAb anti-human CD2

Bio X Cell

InVivoMAb anti-human CD2

7

Research Use Only

Monoclonal

LO-CD2a

4-11 mg/ml

Rat

IgG2b

The LO-CD2a monoclonal antibody reacts with human T-cell surface antigen CD2, also known as SRBC, LFA-2, LFA-3 receptor, rosette receptor, and T-cell surface antigen T11/Leu-5. CD2 is a 45–55 kDa single-pass type I membrane glycoprotein from the immunoglobulin superfamily. CD2 is expressed by 80–90% of human peripheral blood lymphocytes, 95% of thymocytes, E-rosette-forming T cells, a subset of NK cells, and a small proportion (9–12%) of bone marrow cells. CD2 functions as an adhesion receptor that binds to its ligand CD58 (LFA-3), resulting in the activation of CD2-positive T cells and NK cells and in the regulation of their cytolytic activities. CD2 also interacts with CD48, CD2AP, PSTPIP1, and FCGR3A. The LO-CD2a antibody (also called BTI-322) was developed as an immunosuppressive agent for use in experiments involving allotransplantation of organs to prevent graft rejection. The LO-CD2a antibody has been shown to induce CD2+ T-cell depletion through NK cell-mediated ADCC and strongly inhibit in vitro mixed lymphocyte reaction (MLR) in mixed lymphocyte culture (MLC). Further, in a range of in vitro experiments, the LO-CD2a monoclonal antibody inhibited soluble OKT-3, stimulated proliferation of PBMCs, and demonstrated immunosuppressive activities in functional assays. Several in vivo studies have documented the effective CD2+ T cell depletion and graft rejection prevention efficacy of the LO-CD2a antibody.

Human

2°C to 8°C

12352203